CVE-2023-53734
Essential information
- Published
- 04/12/2025 21:16
- Modified
- 08/12/2025 18:27
- Author
- —
- Creator
- —
- CVSS
- 8.7 HIGH (v3) 8.7 HIGH (v4.0)
- CISA KEV
- No
- CWE
- —
- CVSS vector
-
—
—
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
CVSS metrics
- Access vector
- —
- Access complexity
- —
- Authentication
- —
- Confidentiality impact
- —
- Integrity impact
- —
- Availability impact
- —
- Exploitability
- —
- Remediation level
- —
- Report confidence
- —
- Temporal score
- —
- Attack vector
- —
- Attack complexity
- —
- Privileges required
- —
- User interaction
- —
- Scope
- —
- Confidentiality impact
- —
- Integrity impact
- —
- Availability impact
- —
- Exploit code maturity
- —
- Remediation level
- —
- Report confidence
- —
- Temporal score
- —
- Attack vector
- NETWORK
- Attack complexity
- LOW
- Attack requirements
- NONE
- Privileges required
- NONE
- User interaction
- NONE
- Confidentiality (V)
- HIGH
- Confidentiality (S)
- NONE
- Integrity (V)
- NONE
- Integrity (S)
- NONE
- Availability (V)
- NONE
- Availability (S)
- NONE
- Exploit maturity
- NOT_DEFINED
Description
dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.
NVD status
- Status
- Awaiting Analysis — CVE has been marked for Analysis. Normally once in this state the CVE will be analyzed by NVD staff within 24 hours.
- Source
- [email protected]
- NVD
- View on NVD